No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?
Jürgen Braun, Robert Landewé
Topics & Concepts
MedicineUstekinumabPsoriatic arthritisAnkylosing spondylitisSecukinumabIxekizumabPsoriasisPost-hoc analysisInternal medicineSpondylitisPhysical therapyInterleukin 23Axial spondyloarthritisRandomized controlled trialArthritisAdalimumabDermatologyInterleukin 17InflammationDiseaseSacroiliitisSpondyloarthritis Studies and TreatmentsPsoriasis: Treatment and PathogenesisAutoimmune and Inflammatory Disorders Research